knowledge -WSS

knowledge

author：fashion 2025-10-01 21:12:57 - browse：76711

Illustration of a red human heart with an EKG line in the middle. -- health coverage from STAT — Adobe

Just weeks after Novo Nordisk announced that its obesity drug Wegovy cut the risk of heart complications in a major trial, the company now has results from a different study showing the treatment can also benefit people with a common type of heart failure.

The results, published Friday in the New England Journal of Medicine, found that among people with obesity and heart failure with preserved ejection fraction, or HFpEF, those taking Wegovy experienced greater improvements in symptoms and physical function compared with those on placebo. The improvements were greater than what’s been seen in trials of some other HFpEF treatments.

Novo previously shared topline results in investor calls, but the new study contains the full findings, which are also being presented at the European Society of Cardiology conference this week.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

Wikipedia

focus

WSS

Weighted lottery helped low

Surge in Apellis stock fueled by confidence in safety of its eye drug

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Ethical issues complicate the benefits of medical crowdfunding

Humana sues Biden admin over Medicare Advantage audit rule

focus

knowledge

hotspot

Supreme Court strikes down use of affirmative action

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

United colonoscopy coverage change 'may cost lives,' doctors say

Illinois Supreme Court finds assault weapons ban constitutional

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Schizophrenia gene found to be linked to cells' energy dysfunction

Activists slam private health insurers over coverage restrictions

Novo Nordisk touts Wegovy study, but still struggling with supply

Medical leaders decry Supreme Court decision on affirmative action

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

explore

Dozens dead from Maui wildfires: What we know about the victims

NIH nominee Bertagnolli will get October confirmation hearing

Hospitals are dialing back on venture capital investing

Illinois Supreme Court finds assault weapons ban constitutional

Novo Nordisk touts Wegovy study, but still struggling with supply

Illinois Supreme Court finds assault weapons ban constitutional

leisure time

Wikipedia

focus

focus